

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) A method for inhibiting a malignant cell phenotype in a subject, said method comprising: administering to cells a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that produces vasodilation, and wherein said low dose does not induce substantial tolerance.

2. (canceled)

3. (currently amended) The method of claim 1 ~~[[or 2]]~~ wherein administration of the nitric oxide mimetic inhibits metastases and development of resistance to antimalignant therapeutic modalities in the cells.

4. (currently amended) The method of claim 1 ~~[[or 2]]~~ wherein administration of the nitric oxide mimetic inhibits development of a more aggressive malignant cell phenotype in the cells upon administration of an anti-VEGF agent.

5. (currently amended) The method of claim1 ~~[[or 2]]~~ wherein administration of the nitric oxide mimetic inhibits development of a malignant cell phenotype in cells exposed to factors which lower cellular nitric oxide mimetic activity.

6-7. (canceled)

8. (cancelled)

9-12. (canceled)

13. (currently amended) A method for inhibiting a malignant cell phenotype in an animal, said method comprising: administering to said animal in need thereof a low dose of a

nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that produces vasodilation, and wherein said low dose does not induce substantial tolerance.

14-15. (canceled)

16. (original) The method of claim 13 wherein administration of the nitric oxide mimetic inhibits tumor metastases and development of resistance to antimalignant therapeutic modalities in cells in the animal.

17. (original) The method of claim 13 wherein administration of the nitric oxide mimetic inhibits development of a more aggressive malignant cell phenotype in cells in the animal upon administration of an anti-VEGF agent to the animal.

18. (original) The method of claim 13 wherein administration of the nitric oxide mimetic inhibits development of a malignant cell phenotype in animals exposed to factors which lower cellular nitric oxide mimetic activity.

19. (currently amended) A method of treating cancer in a subject, said method comprising administering to said subject in need thereof a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that produces vasodilation, and wherein said low dose does not induce substantial tolerance.

20-21. (canceled)

22. (original) The method of claim 19 wherein the cancer is prostate cancer.

23-29. (canceled)

30-32. (canceled)

33. (currently amended) A method for inhibiting a malignant cell phenotype, said method comprising administering to cells a low dose of a nitric oxide mimetic, wherein said

low dose is between about 10^{-14} M to about 10^{-6} M of said nitric oxide mimetic, and wherein said low dose is 3 to 10,000 fold lower than a dose of the nitric oxide mimetic that produces vasodilation.

34. (previously presented) The method of claim 33, wherein said low dose is between about 10^{-14} M to about 10^{-10} M of said nitric oxide mimetic.

35.-40 (cancelled)